ImmuCell Corporation Revenue 2017–2025

Revenue Gross Profit Operating Income EBITDA Net Income EPS Shares Outstanding

ImmuCell Corporation annual/quarterly revenue history and growth rate from 2017 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.

ImmuCell Corporation revenue for the quarter ending March 31, 2026 was 10.4 M, a 28.39% increase year-over-year.
ImmuCell Corporation revenue for the twelve months ending March 31, 2026 was 30.4 M, a 25.84% increase year-over-year.
ImmuCell Corporation annual revenue for 2025 was 27.6 M, a 4.34% increase from 2024.
ImmuCell Corporation annual revenue for 2024 was 26.5 M, a 51.64% increase from 2023.
ImmuCell Corporation annual revenue for 2023 was 17.5 M, a 5.90% decrease from 2022.
ImmuCell Corporation annual revenue for 2022 was 18.6 M.

Revenue

TRAILING 12 MONTHS · $B

QUARTERLY · $B

YEAR-OVER-YEAR GROWTH · %

ImmuCell Corporation (ICCC) — Frequently Asked Questions

ImmuCell Corporation (ICCC) is a publicly traded US company. It has a market capitalization of $87M. In fiscal 2025 it reported revenue of $28M and net income of -$1M. Explore ICCC's stock price, financial statements, earnings history, margins and key ratios below.

What is ImmuCell Corporation's market cap?

ImmuCell Corporation (ICCC) has a market capitalization of $87M.

What is the ICCC stock price?

ICCC trades at $9.67 (-1.02% on the day).

How much revenue does ImmuCell Corporation make?

ImmuCell Corporation reported revenue of $28M in fiscal 2025.

Is ICCC profitable?

In fiscal 2025, ImmuCell Corporation reported net income of -$1M.